Welcome to our dedicated page for HOOKIPA Pharma news (Ticker: HOOK), a resource for investors and traders seeking the latest updates and insights on HOOKIPA Pharma stock.
HOOKIPA Pharma Inc. (symbol: HOOK) is a clinical-stage biopharmaceutical company dedicated to the development of immunotherapeutics aimed at preventing and treating infectious diseases and cancer. Leveraging its proprietary arenavirus platform, HOOKIPA has created VaxWave® and TheraT®, groundbreaking technologies that reprogram and stimulate the immune system.
VaxWave® is a replication-deficient viral vector, while TheraT® is an attenuated replicating vector. Both technologies are designed to induce strong pathogen-neutralizing antibodies and CD8+ T cells. Remarkably, these vectors can be administered repeatedly without losing efficacy. TheraT® has shown the ability to stimulate CD8+ T cell responses to tumor antigens, achieving frequencies and potencies comparable to or surpassing those seen in adoptive T cell therapy.
HOOKIPA's viral vectors are administered systemically and target dendritic cells in vivo, effectively activating the immune system. This capability is particularly beneficial in the field of immuno-oncology, where it allows for the systemic combating of both primary and metastatic solid tumors.
In recent achievements, HOOKIPA has successfully completed a Phase 1 clinical trial, demonstrating the potential and safety of its innovative approaches. The company continues to focus on advancing its pipeline, which includes the development of an arenavirus-based immunotherapy for KRAS mutant cancer and a neoadjuvant HPV16-specific immunotherapy combined with chemotherapy for HPV16-positive oropharyngeal cancer.
As of December 31, 2023, the company maintains a robust financial position. HOOKIPA remains committed to pioneering immune-based treatments that offer hope for patients with infectious diseases and cancer, positioning itself at the forefront of biopharmaceutical innovation.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) announced its participation in virtual investor meetings and its presentation at The JMP Securities Hematology and Oncology Summit on December 6-7, 2021. The corporate presentation is scheduled for December 7 at 1:20 PM EST, and a webcast will be available on HOOKIPA’s website for 30 days post-event. HOOKIPA is focused on developing immunotherapies using its proprietary arenavirus platform to target various cancers and aims for functional cures of HBV and HIV with Gilead's collaboration.
HOOKIPA Pharma will participate in the Stifel 2021 Virtual Healthcare Conference from November 15-17, 2021. The company’s corporate presentation is scheduled for November 15 at 10:40 AM EST. Interested parties can access the webcast through this link. An archive will be available for 30 days.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) announces advancements in its oncology pipeline, particularly regarding the HB-201 program. The company is collaborating with Merck & Co. to evaluate HB-201 in combination with pembrolizumab for head and neck cancer patients. Recent interim data for HB-200 shows a 75% disease control rate. However, the financial results reveal a net loss of $20 million for Q3 2021, up from $13.6 million in the same period last year, attributed to increased R&D expenses. HOOK's cash position has also decreased from $143.2 million to $82.7 million.
HOOKIPA Pharma has announced the advancement of HB-201 to Phase 2 clinical trials, targeting HPV16+ head and neck cancers in combination with pembrolizumab. This follows impressive interim Phase 1 data showing a 75% disease control rate and significant tumor shrinkage. In addition, HB-200 demonstrated early anti-tumor activity with 53% of patients experiencing tumor reduction. HOOKIPA is also expanding its oncology pipeline with HB-300 and HB-700 for other cancers, while continuing its promising HB-101 program for kidney transplant patients. Investor insights will be shared in an upcoming call.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) announced it will release its third quarter financial results on November 10, 2021, before market opening. Notably, the company is focusing on developing a new class of immunotherapeutics based on its proprietary arenavirus platform, which activates the immune system against diseases. HOOKIPA is advancing its lead oncology products, HB-201 and HB-202, in clinical trials targeting HPV-related cancers, alongside a CMV vaccine candidate, HB-101. The company also collaborates with Gilead Sciences to research HIV and Hepatitis B treatments.
HOOKIPA Pharma has published a comprehensive review in Frontiers in Oncology, emphasizing the potential of its arenavirus platform as a novel immunotherapy for cancer. The review highlights pre-clinical and clinical data demonstrating effective tumor-specific CD8+ T cell responses following treatment with arenaviral immunotherapies like HB-200, particularly for patients with advanced HPV16+ cancer. HOOKIPA plans to advance HB-200 to Phase 2 trials and explore treatments for other cancers. Initial clinical data show promising efficacy, offering hope for improved cancer treatments.
HOOKIPA Pharma (NASDAQ: HOOK) announces a clinical collaboration with Merck to assess HB-200 with KEYTRUDA as a first-line treatment for advanced head and neck squamous cell carcinoma. This initiative follows promising results from the ongoing Phase 1/2 trial, where HB-201 showed an 18% overall response rate and a median progression-free survival of 3.45 months. Planned Phase 2 trials are set for 2022, indicating HOOKIPA's commitment to advancing its immunotherapeutic pipeline targeting HPV16-positive cancers.
HOOKIPA Pharma, listed on NASDAQ as HOOK, announced participation in several upcoming virtual investor conferences. Key events include the Morgan Stanley 19th Annual Global Healthcare Conference on September 9-10 and 13-15, featuring a fireside chat on September 10 at 8:45 AM ET. The H.C. Wainwright 23rd Annual Global Investment Conference is scheduled for September 13-15 with a presentation on September 13 at 7:00 AM ET. Additionally, HOOKIPA will present at the 2021 Cantor Virtual Global Healthcare Conference on September 28 from 8:00-8:30 AM ET. Webcasts will be available on their website.
HOOKIPA Pharma reported its Q2 2021 financial results, highlighting progress in its arenaviral immunotherapy programs. HB-200 for HPV16+ cancers showed promising Phase 1 data, with activated CD8+ T cells reaching up to 40% of the T cell pool. Revenue declined to $5.4 million from $6.7 million year-over-year, attributed to a lack of milestone payments from Gilead. The net loss increased to $17.2 million, up from $7.1 million in Q2 2020. Cash reserves decreased to $102.9 million, down from $143.2 million as of the end of 2020, reflecting increased R&D costs.
HOOKIPA Pharma has published promising pre-clinical data on its arenaviral-based immunotherapeutic targeting melanoma in Nature Communications. A single intra-tumoral injection resulted in tumor regression in all tested mice, achieving tumor cures in approximately 60%. The findings demonstrate the ability to modulate the tumor microenvironment and induce significant T cell responses. HOOKIPA’s ongoing Phase 1/2 trials with their HPV programs further explore this novel therapeutic platform, showcasing potential in cancer treatment and addressing unmet medical needs.
FAQ
What is the current stock price of HOOKIPA Pharma (HOOK)?
What is the market cap of HOOKIPA Pharma (HOOK)?
What does HOOKIPA Pharma Inc. specialize in?
What are VaxWave® and TheraT®?
How do the arenavirus technologies work?
What recent achievements has HOOKIPA made?
How are HOOKIPA's viral vectors administered?
What is the financial condition of the company?
What is the significance of TheraT® in cancer treatment?
Who can be contacted for investor relations?
What are the upcoming projects for HOOKIPA?
What makes HOOKIPA's technologies unique?
